Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression

Annals of the Rheumatic Diseases

Volumn 75, Issue 1, 2016, Pages 303-310

  Iwamoto, Naoki ^a,b   Vettori, Serena ^a   Maurer, Britta ^a   Brock, Matthias ^a   Pachera, Elena ^a   Jüngel, Astrid ^a   Calcagni, Maurizio ^a   Gay, Renate E ^a   Whitfield, Michael L ^c   Distler, Jörg H W ^d   Gay, Steffen ^a   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 193B; UNCLASSIFIED DRUG; UROKINASE; CYTOKINE; MIRN193 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROLIFERATIVE VASCULOPATHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULMONARY ARTERY SMOOTH MUSCLE CELL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; UPREGULATION; VASCULAR DISEASE; BIOSYNTHESIS; CASE CONTROL STUDY; CELL CULTURE; CELL HYPOXIA; FIBROBLAST; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKIN; VASCULAR SMOOTH MUSCLE;

APOPTOSIS; CASE-CONTROL STUDIES; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; FIBROBLASTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84954216511     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205326     Document Type: Article

References (42)

1. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
2. Abraham DJ, Krieg T, Distler J, et al. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009;48(Suppl 3):iii3-7.
3. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
4. Veale DJ, Collidge TA, Belch JJ. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995;54:853-5.
5. Youssef P, Englert H, Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis 1993;52:464-6.
6. Alfano D, Franco P, Vocca I, et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005;93:205-11.
7. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43.
8. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 2002;383:5-19.
9. Tkachuk VA, Plekhanova OS, Parfyonova YV. Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol 2009;87:231-51.
10. Parfyonova Y, Plekhanova O, Solomatina M, et al. Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodelling after arterial injury. J Vasc Res 2004;41:268-76.
11. Plekhanova OS, Parfyonova YV, Bibilashvily R, et al. Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J Hypertens 2000;18:1065-9.
12. D'Alessio S, Fibbi G, Cinelli M, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004;50:3275-85.
13. Margheri F, Manetti M, Serrati S, et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 2006;54:3926-38.
14. Manetti M, Rosa I, Milia AF, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 2014;73:1700-9.
15. Axtell MJ. Evolution of microRNAs and their targets: are all microRNAs biologically relevant? Biochim Biophys Acta 2008;1779:725-34.
16. Olena AF, Patton JG. Genomic organization of microRNAs. J Cell Physiol 2010;222:540-5.
17. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003;115:787-98.
18. Han M, Toli J, Abdellatif M. MicroRNAs in the cardiovascular system. Curr Opin Cardiol 2011;26:181-9.
19. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011;38:724-33.
20. Wilmott JS, Zhang XD, Hersey P, et al. The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology 2011;43:657-71.
21. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.
22. Li H, Yang R, Fan X, et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int 2012;32:307-13.
23. Stanczyk J, Ospelt C, Karouzakis E, et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011;63:373-81.
24. Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010;62:1733-43.
25. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
26. Distler JH, Wenger RH, Gassmann M, et al. Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004;50:10-23.
27. Niederer F, Ospelt C, Brentano F, et al. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann Rheum Dis 2011;70:1866-73.
28. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
29. Unno K, Zhou Y, Zimmerman T, et al. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma 2009; 50:1865-71.
30. Distler JH, Jungel A, Pileckyte M, et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007;56:4203-15.
31. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008;3:e2696.
32. McMurtry MS, Archer SL, Altieri DC, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-91.
33. McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004;95:830-40.
34. Maglott D, Ostell J, Pruitt KD, et al. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2005;33:D54-8.
35. Bandinelli F, Bartoli F, Perfetto E, et al. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). Clin Exp Rheumatol 2005;23:671-7.
36. Postiglione L, Montuori N, Riccio A, et al. The plasminogen activator system in fibroblasts from systemic sclerosis. Int J Immunopathol Pharmacol 2010;23:891-900.
37. Chen J, Zhang X, Lentz C, et al. miR-193b Regulates Mcl-1 in Melanoma. Am J Pathol 2011;179:2162-8.
38. Leivonen SK, Rokka A, Ostling P, et al. Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact. Mol Cell Proteomics 2011;10:M110 005322.
39. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009;28:3937-48.
40. Rauhala HE, Jalava SE, Isotalo J, et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010;127:1363-72.
41. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011;18:1104-10.
42. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-4.